The tweet was deleted by the author.
But we saved everything 🙂.
Michael Taylor has expressed concerns about the business model of Viking Therapeutics (VKTX) following Novo Nordisk's announcement of pricing their oral GLP-1 treatments at approximately $150 per prescription.
Taylor suggests that the cost of goods sold (COGS) for VKTX's oral GLP-1 might significantly exceed this price point, casting doubt on the company's business viability. Despite these challenges, he describes VKTX as an attractive option in speculative contexts.
Such scrutiny of VKTX’s long-term prospects aligns with Taylor’s previous assessments of market volatility following pivotal corporate events, as seen when he dissected the abrupt momentum shift in LAZR after its founder’s departure. Additionally, his current caution stands in contrast to the optimism displayed in his evaluation of a potential bullish trajectory for PCT stock amid speculative interest, illustrating his nuanced approach toward emerging biotech and growth stories.